Also trades as: PAR.AX (ASX) · $vol 0M
PBIGF OTC
Paradigm Biopharmaceuticals Limited
1W: -86.8%
1M: -98.9%
3M: -99.1%
YTD: -99.4%
1Y: -99.2%
3Y: -99.8%
5Y: -99.9%
$0.00
-0.00 (-17.65%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.8M
52W Range0.0014-0.3468
Volume87,000
Avg Volume14,750
Beta-0.01
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOPaul John Rennie
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2019-05-10
Websiteparadigmbiopharma.com
500 Collins Street
Melbourne, VIC 3000
AU
Melbourne, VIC 3000
AU
61 3 9629 5566
About Paradigm Biopharmaceuticals Limited
Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome. The company was established in 2014.
Latest News
No recent news
Recent Insider Trades
No insider trades found